Related Experiment Video
Updated: Jul 9, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Telmisartan improves endothelial function in patients with essential hypertension
Ralf A Benndorf1, Daniel Appel, Renke Maas
1Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, University Medical Center, Hamburg-Eppendorf, Germany. benndorf@uke.uni-hamburg.de
Journal of Cardiovascular Pharmacology
|December 1, 2007
Summary
Telmisartan, an angiotensin receptor blocker (ARB), improved endothelial function in patients with essential hypertension but did not alter renal vascular resistance. This suggests potential cardiovascular benefits independent of blood pressure changes.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Pharmacology
Background:
- Hypertension is a key cardiovascular risk factor linked to endothelial dysfunction and elevated renal vascular resistance.
- Angiotensin receptor blockers (ARBs) may counteract these issues by blocking angiotensin type 1 (AT1) receptor effects.
- This study explored telmisartan's impact on endothelial function and renal vascular resistance in hypertensive patients.
Purpose of the Study:
- To investigate the effects of telmisartan on endothelial function and renal vascular resistance in patients with essential hypertension.
- To compare telmisartan with nisoldipine and their combination in treating hypertension.
Main Methods:
- A 6-week prospective, parallel-group study randomized 37 hypertensive patients to telmisartan, nisoldipine, or combination therapy.
- Brachial artery flow-mediated dilation (FMD) and renal vascular resistance index (RVRI) were measured using high-resolution ultrasound at baseline, 3 weeks, and 6 weeks.
Main Results:
- After 6 weeks, telmisartan (alone or in combination) significantly improved FMD compared to baseline.
- Nisoldipine monotherapy did not significantly alter FMD.
- Neither telmisartan nor nisoldipine significantly changed RVRI at any time point.
Conclusions:
- Telmisartan treatment improved endothelial function (FMD) in patients with essential hypertension.
- Telmisartan did not significantly affect renal vascular resistance (RVRI).
- Further research is needed to determine if telmisartan's effect on FMD contributes to blood pressure-independent cardiovascular risk reduction.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...